Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer
Qinchuan Wu,Wuhua Zhou,Shengyong Yin,Yuan Zhou,Tianchi Chen,Junjie Qian,Rong Su,Hong Liangjie,H. Lu,Feng Zhang,Haiyang Xie,Lin Zhou,Shusen Zheng +12 more
Reads0
Chats0
TLDR
It is highlighted that the hypoxic environment initiated the onset of tumor immunosuppression through TREM‐1+ TAMs attracting CCR6+Foxp3+ Tregs, and TREM-1- TAMs endowed HCC with anti‐PD‐L1 therapy resistance.About:
This article is published in Hepatology.The article was published on 2019-07-01 and is currently open access. It has received 147 citations till now. The article focuses on the topics: Tumor microenvironment & Tumor progression.read more
Citations
More filters
Journal ArticleDOI
Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Chen Lu,Dawei Rong,Dawei Rong,Betty Zhang,Wubin Zheng,Xuehao Wang,Xuehao Wang,Ziyi Chen,Weiwei Tang +8 more
TL;DR: The current concepts of immunosuppressive cells, including tumor-associated macrophages, marrow-derived suppressor cells, tumor- associated neutrophils, cancer-associated fibroblasts, and regulatory T cell interactions to actively promote tumorigenesis are discussed.
Journal ArticleDOI
Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities.
TL;DR: Novel findings regarding the origins and functions of hepatic macrophages are highlighted, the potential of targeting macrophage subsets and their plasticity explain their different functional responses in distinct liver diseases are discussed.
Journal ArticleDOI
Targeting tumor-associated macrophages to synergize tumor immunotherapy.
TL;DR: In this paper, the authors summarize recent studies investigating the involvement of TAMs in immune checkpoint inhibition, tumor vaccines and adoptive cell transfer therapies, and discuss the therapeutic potential of targeting TAMs as an adjuvant therapy in tumor immunotherapies.
Journal ArticleDOI
Chemokines and the immune response to cancer.
TL;DR: In this paper, the role of the chemokine system in anti-tumor and Pro-Tumor immune responses is discussed and discussed how malignant cells and the tumor microenvironment regulate the overall chemokines landscape to shape the type and outcome of immune responses to cancer and cancer treatment.
Journal ArticleDOI
Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.
TL;DR: The mechanism underlying the ineffectiveness of these targeted therapies, including oncogenic alterations in driver genes and downstream pathways, high heterogeneity of HCC, and the mutual interaction of tumor microenvironment that promotes therapeutic resistance are highlighted.
References
More filters
Journal ArticleDOI
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh,Christina L. Harview,Jennifer H. Yearley,I. Peter Shintaku,Emma Taylor,Lidia Robert,Bartosz Chmielowski,Marko Spasic,Gina Henry,Voicu Ciobanu,Alisha N. West,Manuel Carmona,Christine Kivork,Elizabeth Seja,Grace Cherry,Antonio Gutierrez,Tristan Grogan,Christine Mateus,Gorana Tomasic,John A. Glaspy,Ryan O. Emerson,Harlan Robins,Robert H. Pierce,David Elashoff,Caroline Robert,Antoni Ribas +25 more
TL;DR: It is shown that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.
Journal ArticleDOI
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li,Taiwen Li,Jingyu Fan,Binbin Wang,Nicole Traugh,Qianming Chen,Jun Liu,Bo Li,X. Shirley Liu,X. Shirley Liu +9 more
TL;DR: Tumor Immune Estimation Resource (TIMER) is presented to comprehensively investigate molecular characterization of tumor-immune interactions and provides a user-friendly web interface for dynamic analysis and visualization of these associations, which will be of broad utilities to cancer researchers.
Journal ArticleDOI
Tumor-associated macrophages: from mechanisms to therapy.
TL;DR: Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.
Journal ArticleDOI
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani,Federica Marchesi,Federica Marchesi,Alberto Malesci,Alberto Malesci,Luigi Laghi,Paola Allavena +6 more
TL;DR: It is surmised that TAMs can provide tools to tailor the use of cytoreductive therapies and immunotherapy in a personalized medicine approach, and that TAM-focused therapeutic strategies have the potential to complement and synergize with both chemotherapy and immunotherapies.
Journal ArticleDOI
Hypoxia in cancer: significance and impact on clinical outcome
Peter Vaupel,Arnulf Mayer +1 more
TL;DR: In this article, the authors suggest that hypoxia is prognostic for survival and local control in head and neck cancers, and use endogenous proteins (e.g., HIF-1α, GLUT-1, CA IX) or exogenous bioreductive drugs.
Related Papers (5)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Targeting macrophages: therapeutic approaches in cancer.
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more